Balancing safety and efficacy in pediatric asthma management

Pediatrics

Volumn 109, Issue 2 II, 2002, Pages 381-392

  Skoner, David P ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Airway deposition; Bioavailability; Inhaled corticosteroids; Leukotriene receptor antagonists; Pediatric asthma

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHROMONE DERIVATIVE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; GROWTH HORMONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLXANTHINE DERIVATIVE; MONTELUKAST; NEDOCROMIL SODIUM; SALMETEROL; THEOPHYLLINE; ZAFIRLUKAST;

ASTHMA; CHILD; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GROWTH INHIBITION; GROWTH RETARDATION; HORMONE ACTION; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL AVAILABILITY; CHILD, PRESCHOOL; CHROMONES; GROWTH DISORDERS; HUMANS; INFANT; LEUKOTRIENE ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE; THEOPHYLLINE;

EID: 0036159288     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Asthma in children
2. Budesonide treatment of moderate and severe asthma in children: A dose-response study
3. Efficacy and safety of budesonide inhalation suspension (pulmicort respules) in young children with inhaled steroid-dependent, persistent asthma
4. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma
5. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children
6. Budesonide in patients with mild asthma
7. Effect of early vs late intervention wtih inhaled corticosteroids in asthma
8. Relationships between duration of asthma and asthma severity among children in the childhood asthma management program
9. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium
10. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: Evidence that the specific drug being delivered is an important consideration
11. Pharmacokinetic and pharmacodynamic evolution of fluticasone propionate after inhaled administration
12. Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids
13. A comparison of terbutalizne inhaled by Turbuhaler and by a chlorofluorocarbon (CFC) inhaler in children with exercise-induced asthma
14. Effect of formulation parameters on hydrofluoralkane-beclomethasone dipropionate drug deposition in humans
15. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant
16. Differences in lung bioavailability between different propellants for fluticasone propionate
17. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate
18. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction
19. Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects
20. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients
21. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study
22. Longterm effects of budesonide or nedocromil in children with asthma
23. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma
24. Target height as predicted by parental heights in a population-based study
25. Adverse effects of inhaled (800 mcg) on growth and collagen turnover in children with asthma: A double-blind comparison of once-daily versus twice-daily administration
26. Absence of growth retardation in children with perennial allergic rhinitis after 1 year of treatment with mometasone furoate aqueous nasal spray
27. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate
28. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide
29. Disodium cromoglycate (FPL 670) ('Intal'): A specific inhibitor of reaginic antibody-antigen mechanisms
30. Evaluation of the addition of cromolyn sodium to bronchodilator maintenance therapy in the long-term management of asthma
31. Inhaled lactose-free sodium cromoglycate powder in the treatment of recurrent asthma
32. Montelukast (MK-0476), a CysLT1 receptor antagonist, improves the signs and symptoms over one year of treatment
33. A controlled study of cromolyn sodium sponsored by the Drug Committee of the American Academy of Allergy
34. Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1-4 year-old children with moderate asthma
35. Clinical benefits of cromolyn sodium aerosol (MDI) in the treatment of asthma in children
36. Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: A double blind study
37. A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma
38. Nebulized sodium cromoglycate in young asthmatic children. Double-blind trial
39. Controlled trial of cromoglycate and slow-release aminophylline in perennial childhood asthma
40. Nebulised cromoglycate, theophylline, and placebo in preschool asthmatic children
41. A clinical trial of combined cromolyn/beclomethasone treatment for chronic asthma
42. The combined use of betamethasone valerate and sodium cromoglycate in the treatment of asthma
43. Betamethasone 17 valerate aerosol and disodium chromoglycate in severe childhood asthma
44. Drugs used in the treatment of asthma
45. A placebo-controlled, blind comparison of nedocromil sodium and beclomethasone dipropionate in bronchial asthma
46. A group comparative study of the safety and efficacy of nedocromil sodium (tilade) in reversible airways disease: A preliminary report
47. Effects of the addition of nedocromil sodium to maintenance bronchodilator therapy in the management of chronic asthma
48. Double blind, placebo controlled study of nedocromil sodium in asthma
49. A double-blind, placebo-controlled study to assess the efficacy of nedocromil sodium in the management of childhood grass-pollen asthma
50. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects
51. High-dose nedocromil sodium as an addition to inhaled corticosteroids in the treatment of asthma
52. Nedocromil sodium in adults with asthma dependent on inhaled corticosteroids: A double blind, placebo controlled study
53. A comparative study of the clinical efficacy of nedocromil sodium and placebo: How does cromolyn sodium compare as an active control treatment?
54. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice
55. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma
56. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma
57. The value of maintenance theophylline in steroid-dependent asthma
58. Behavior abnormalities and poor school performance due to oral theophylline use
59. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children
60. Leukotrienes as mediators of airway obstruction
61. Slow reacting substances of anaphylaxis: Identification of leukotrienes C-1 and D from human and rat sources
62. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children
63. Montelukast added to budesonide in children with persistent asthma: A randomized, double-blind crossover study
64. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study
65. A drug interaction between zafirlukast and theophylline
66. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized double-blind trial
67. Leukotriene receptor antagonists: Efficacy and safety in children with asthma
68. Montelukast (MK-0476) improves asthma over a 3 month treatment period in 2- to 5-year olds [abstract]
69. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years
70. Efficacy and safety of salmeterol in childhood asthma
71. A one-week doseranging study of inhaled salmeterol in children with asthma
72. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma
73. Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children
74. A comparison of beclomethasone, salmeterol, and placebo in children with asthma
75. One year treatment with salmeterol compared with beclomethasone in children with asthma
76. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma
77. Regular inhaled salbutamol and airway responsiveness to allergen
78. Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma
79. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol
80. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta-2 agonist
81. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucorticoid treatment
82. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol
83. Salmeterol xinafoate in children on high dose inhaled steroids
84. Poverty, race, and medication use are correlates of asthma hospitalization rates: A small area analysis in Boston
85. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients
86. Comparison of patient's compliance with prescribed oral and inhaled asthma medications
87. Montelukast versus cromolyn for treatment of 6-11 year old children with asthma
88. Insight into patient dissatisfaction with asthma treatment